Folia Medica 63(4): 586-590, doi: 10.3897/folmed.63.e56124

Concurrent treatment of HIV, disseminated Mycobacterium avium complex and HCV-infection

Vera Zimina^‡, Svetlana Degtyareva^‡, Elena Beloborodova^‡, Julia Klimova^‡, Alexey Kravchenko^§

‡ RUDN University, Moscow, Russia§ Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow, Russia

Corresponding author: Svetlana Degtyareva ( degtyareva_syu@pfur.ru )

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Zimina V, Degtyareva S, Beloborodova E, Klimova J, Kravchenko A (2021) Concurrent treatment of HIV, disseminated Mycobacterium avium complex and HCV-infection. Folia Medica 63(4): 586-590. https://doi.org/10.3897/folmed.63.e56124

Abstract

Patients with HIV-infection diagnosed at late stages usually have significant immunosuppression and demand simultaneous antiretroviral therapy and treatment of opportunistic infections. The presence of HCV coinfection makes treatment even more challenging because of possible adverse effects and drug-drug interactions. HCV cure in such clinical situations not only prevents fibrosis progression, but can also enhance virologic and/or immunologic response to antiretrovirals and thus effective treatment of opportunistic infections. Thorough consideration of all existing diseases and drug interactions of the combined therapy makes simultaneous treatment of HIV, chronic hepatitis C, and opportunistic infections not only possible but the best way to improve outcomes in a complex clinical situation.

Keywords

co-infection, drug interactions, hepatitis C, immunosuppression, non-tuberculous mycobacteria